Patent intelligence · KR
KR 20230088753
파킨슨병 치료를 위한 오피카폰 및 레보도파
파킨슨병 치료를 위한 오피카폰 및 레보도파
Patent details — KR 20230088753
- Jurisdiction
- KR
- Status
- granted
- Grant date
- Jun 20, 2023
- Expiration
- Jun 15, 2043
- Applicant
- BIAL PORTELA & CA SA [PT]
- CPC classes
- A61K 31/ 198 A I, A61K 31/ 4439 A I, A61K/31165, A61K/31198
Quick answer
KR 20230088753 (파킨슨병 치료를 위한 오피카폰 및 레보도파) is held by BIAL PORTELA & CA SA [PT]. Status: granted. Granted Jun 20, 2023. Expires Jun 15, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIAL PORTELA & CA SA [PT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 198 A I, A61K 31/ 4439 A I, A61K/31165, A61K/31198, A61K/314439, A61K/4506
More from BIAL PORTELA & CA SA [PT]
Related pharmaceutical patents in our USPTO index.
-
WO 2026106499
ANTAGONISTES DU RÉCEPTEUR DE L'ORÉXINE : COMPOSÉS 2-AZABICYCLIQUES
granted -
WO 2026015039
THÉRAPIE GÉNIQUE POUR LE TRAITEMENT DE L'ENCÉPHALOPATHIE ÉPILEPTIQUE ASSOCIÉE À LA SYNGAP1
granted -
WO 2025211975
AGONISTES DU RÉCEPTEUR DE L'OREXINE
granted -
WO 2025023852
ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE
granted -
WO 2025023851
ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE
granted -
WO 2024242579
RÉGIMES DE TRAITEMENT DE LA MALADIE DE PARKINSON IDIOPATHIQUE PRÉCOCE
granted -
AU 2023244944
PRODRUGS OF OPICAPONE
granted -
WO 2024039256
RÉGIMES THÉRAPEUTIQUES POUR LA MALADIE DE PARKINSON
granted
Frequently asked questions
What is US patent 20230088753?
KR 20230088753 (파킨슨병 치료를 위한 오피카폰 및 레보도파) is held by BIAL PORTELA & CA SA [PT]. Status: granted. Granted Jun 20, 2023. Expires Jun 15, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns KR 20230088753?
BIAL PORTELA & CA SA [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does KR 20230088753 expire?
Our index shows an expiration date of Jun 15, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.